A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% in Pediatric Subjects With Mild to Moderate Atopic Dermatitis Followed by an Open Label Extension
Phase of Trial: Phase II
Latest Information Update: 10 May 2016
At a glance
- Drugs MRX 6 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Celsus Therapeutics
- 05 May 2016 Status changed from active, no longer recruiting to discontinued.
- 17 Feb 2015 Status changed from recruiting to active, no longer recruiting, based on information in the Celsus Therapeutics media release.
- 17 Feb 2015 Results published in the Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History